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pityriasis rosea is associated with reactivation of humanvaccination
Dear Editor,
We  read with great interest the review by Gonc¸alves et al.1
about safety, tolerability and side effects of human papil-
lomavirus (HPV) vaccines, discussing the most frequently
reported events related to the vaccine. We  agree that safety is
not a major barrier to vaccination since most of the reported
adverse events have been mild or moderate in intensity. We
would like to describe two patients who developed pityria-
sis rosea (PR) following the last dose of the quadrivalent HPV
vaccine. To our knowledge, they are the ﬁrst two cases of PR
secondary to HPV vaccine.
The ﬁrst of our patients was a 17-year-old woman who
presented with a typical PR, which developed one month
after the third dose of HPV vaccination. The exanthema, pre-
ceded by general malaise and headache, started with a herald
patch on the trunk and progressed with secondary eruptions
on trunk, arms and neck two weeks later. Routine investi-
gations yielded unremarkable results. Serology disclosed IgG
(1/160) and IgM (1/320) antibodies against human herpesvirus
7 (HHV-7) and IgG antibody against human herpesvirus 6
(HHV-6) (1/40). HHV-7 DNA in plasma (170 genome equiva-
lents/mL) and in peripheral blood mononuclear cells (PBMCs)
(657 genome equivalents/mL) were found by calibrated quan-
titative real-time polymerase chain reaction, as reported.2
HHV-6 DNA was neither found in plasma nor in PBMCs. Her
lesions and symptoms gradually improved in the following
eight weeks. After recovery, HHV-7 DNA was not any longer
detected in plasma.
Our second patient was a 20-year-old woman who devel-
oped a typical PR two months after the third dose of HPV
vaccination. The skin eruption was preceded by headache,
inability to concentrate, and insomnia, initiated over the trunk
and then spread to the abdomen and neck without a herald
patch. Routine investigations turned out normal. IgG antibod-
ies against HHV-6 and HHV-7 were present (1/320 and 1/160,
respectively) whereas IgM was negative. HHV-6 and HHV-7
DNAs were positive in plasma (137 and 85 copies/mL) and in
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3PBMCs (570 and 464 copies/mL). The lesions improved in eight
weeks. HHV-6 and HHV-7 DNAs were no longer detected after
recovery.
Pityriasis rosea (PR) is a self-limiting exanthematic disease,
due to an endogenous reactivation of HHV-6 and/or HHV-
7.2 PR and PR-like eruptions have very rarely been described
after vaccination against diphtheria, tuberculosis, poliomyeli-
tis, tetanus3 but never after HPV vaccination. PR, usually,
develops a few weeks after vaccination.
According to the criteria recently described,4 in our
patients, the detection of HHV-7 and HHV-6 viremia, together
with anti-HHV-7 IgM antibodies in the plasma of the ﬁrst
patient, conﬁrmed that the exanthematic lesions were typical
PR instead of PR-like eruptions.
The pathogenetic mechanisms leading to post-vaccination
PR is unknown. We  believe that the non-speciﬁc immune stim-
ulation and the subsequent release of cytokines5 may trigger
HHV-6 and/or HHV-7 reactivation and therefore the occur-
rence of PR. However, PR is a self-limiting exanthema and its
occurrence does not require discontinuation of the vaccina-
tion schedule.
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